SCHEDULE: Armistice Capital Boosts Rigel Pharma Stake to 8.92%
Beneficial Ownership Report (Amendment)
Armistice Capital, LLC and Steven Boyd have filed an Amendment No. 5 to their Schedule 13G, reporting beneficial ownership of 8.92% of Rigel Pharmaceuticals, Inc.'s common stock.
Summary
- Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 1,600,000 shares of Rigel Pharmaceuticals, Inc. common stock.
- This ownership represents 8.92% of the company's outstanding common stock.
- The percentage is calculated based on 17,937,340 shares outstanding as of July 31, 2025, as reported in Rigel Pharmaceuticals' Form 10-Q filed on August 5, 2025.
- Armistice Capital, LLC, as the investment manager, exercises voting and investment power over the securities held by Armistice Capital Master Fund Ltd., the direct holder of the shares.
- Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
- The filing is an Amendment No. 5 to a previously filed Schedule 13G, indicating an update to an existing significant stake.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. It indicates a continued significant stake by an institutional investor.
Positives
- NA This filing is a beneficial ownership disclosure and does not contain information typically categorized as positives regarding company performance or operations.
Negatives
- NA This filing is a beneficial ownership disclosure and does not contain information typically categorized as negatives regarding company performance or operations.
Risks
- NA This filing is a beneficial ownership disclosure and does not contain information regarding company-specific risks.
Future Outlook
NA This filing is a beneficial ownership disclosure and does not contain forward-looking statements or guidance from the issuer or reporting persons regarding the issuer's future operations.
Industry Context
The filing of a Schedule 13G by an investment firm like Armistice Capital, LLC, is a standard regulatory disclosure for institutional investors acquiring significant passive stakes (5% or more) in publicly traded companies, common across all industries, including the biotechnology and pharmaceutical sectors.
Comparison to Industry Standards
- NA This filing is a beneficial ownership disclosure and does not contain performance metrics or operational results that can be directly compared to industry benchmarks or specific comparable companies/projects.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA This filing is a beneficial ownership disclosure and does not report on any litigation or regulatory matters concerning the issuer.
Related Party Transactions
- NA This filing is a beneficial ownership disclosure and does not report on any disclosed related party dealings of the issuer.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can be viewed as a vote of confidence or a signal of continued interest.
- Investment Professionals: Offers updated data on institutional ownership for market analysis and investment decision-making.
Next Steps
- NA This filing is a regulatory disclosure of current ownership and does not outline future actions or milestones for the issuer or reporting persons beyond ongoing compliance.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement. |
| 07/31/2025 | Date as of which the number of outstanding shares (17,937,340) was reported by the Issuer. |
| 08/05/2025 | Date Rigel Pharmaceuticals, Inc. filed its Form 10-Q with the SEC, reporting shares outstanding. |
| 08/14/2025 | Date of signing and filing of this Schedule 13G Amendment No. 5. |
Keywords
Rigel Pharmaceuticals, Armistice Capital, Steven Boyd, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.